MA29120B1 - Sel de potassium d'un inhibiteur de l'integrase du vih - Google Patents

Sel de potassium d'un inhibiteur de l'integrase du vih

Info

Publication number: MA29120B1
Authority: MA; Morocco
Prior art keywords: inhibitor; potassium salt; hiv integrase; integrase; hiv
Prior art date: 2004-12-03

Application number

MA30041A

Other languages

English (en)

Inventor

Kevin M Belyk

Henry G Morrison

Philip Jones

Vincenzo Summa

Original Assignee

Angeletti P Ist Richerche Bio

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-03

Filing date

2007-06-29

Publication date

2007-12-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36171569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29120(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-29 Application filed by Angeletti P Ist Richerche Bio, Merck Sharp & Dohme filed Critical Angeletti P Ist Richerche Bio

2007-12-03 Publication of MA29120B1 publication Critical patent/MA29120B1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA30041A 2004-12-03 2007-06-29 Sel de potassium d'un inhibiteur de l'integrase du vih MA29120B1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US63313204P	2004-12-03	2004-12-03

Publications (1)

Publication Number	Publication Date
MA29120B1 true MA29120B1 (fr)	2007-12-03

Family

ID=36171569

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA30041A MA29120B1 (fr)	2004-12-03	2007-06-29	Sel de potassium d'un inhibiteur de l'integrase du vih

Country Status (35)

Country	Link
US (2)	US7754731B2 (fr)
EP (2)	EP1819700B1 (fr)
JP (1)	JP4705956B2 (fr)
KR (2)	KR20130122031A (fr)
CN (1)	CN101068793B (fr)
AR (2)	AR052034A1 (fr)
AT (2)	ATE518844T1 (fr)
AU (1)	AU2005311671B8 (fr)
BR (1)	BRPI0518760A8 (fr)
CA (1)	CA2588398C (fr)
CR (1)	CR9146A (fr)
CY (1)	CY1112859T1 (fr)
DK (1)	DK1819700T3 (fr)
EA (1)	EA012418B1 (fr)
ES (2)	ES2370136T3 (fr)
GE (1)	GEP20105086B (fr)
HR (1)	HRP20120066T1 (fr)
IL (1)	IL183614A (fr)
MA (1)	MA29120B1 (fr)
ME (1)	ME01985B (fr)
MX (1)	MX2007006639A (fr)
MY (1)	MY144320A (fr)
NI (1)	NI200700138A (fr)
NO (1)	NO338784B1 (fr)
NZ (1)	NZ555376A (fr)
PE (1)	PE20061148A1 (fr)
PL (1)	PL1819700T3 (fr)
PT (1)	PT1819700E (fr)
RS (1)	RS52197B (fr)
SI (1)	SI1819700T1 (fr)
TN (1)	TNSN07215A1 (fr)
TW (1)	TWI344463B (fr)
UA (1)	UA87884C2 (fr)
WO (2)	WO2006060730A2 (fr)
ZA (1)	ZA200704130B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1725528T3 (da)	2004-03-11	2013-09-02	4Sc Ag	Sulfonylpyrroler som hdac-inhibitorer
JP2008521929A (ja) *	2004-12-03	2008-06-26	メルクエンドカムパニーインコーポレーテッド	抗核形成剤を含有する医薬組成物
RU2382648C2 (ru) *	2004-12-03	2010-02-27	Мерк Энд Ко., Инк.	Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
CA2588466A1 (fr) *	2004-12-03	2006-06-08	Merck & Co., Inc.	Utilisation d'atazanavir afin d'ameliorer les proprietes pharmacocinetiques de medicaments metabolises par ugt1a1
BRPI0708470A2 (pt) *	2006-03-14	2011-05-31	Merck & Co Inc	processo para a produção de partìculas cristalinas de um composto ativo orgánico, e, composição farmacêutica
AU2007275805A1 (en)	2006-07-19	2008-01-24	University Of Georgia Research Foundation, Inc.	Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy
US7687509B2 (en)	2007-07-09	2010-03-30	Concert Pharmaceuticals Inc.	Pyrimidinecarboxamide derivatives
JP5564435B2 (ja) *	2008-01-08	2014-07-30	メルク・シャープ・アンド・ドーム・コーポレーション	Ｎ−置換ヒドロキシピリミジノンカルボキサミドの製造方法
ES2549387T3 (es)	2009-06-02	2015-10-27	Hetero Research Foundation	Procedimiento de preparación de raltegravir potásico amorfo
WO2011024192A2 (fr)	2009-07-27	2011-03-03	Matrix Laboratories Ltd	Nouveaux polymorphes du raltegravir
BR112012009857A8 (pt)	2009-10-26	2023-04-11	Merck Sharp & Dohme	Composições farmacêuticas sólidas contendo um inibidor de integrase
DE102009056636A1 (de)	2009-12-02	2011-06-09	Ratiopharm Gmbh	Raltegravir-Polymorphe
CN102753526B (zh)	2009-12-07	2014-11-26	佐治亚大学研究基金会	吡啶酮羟基环戊基羧酰胺：具有治疗用途的hiv 整合酶抑制剂
ES2362598B1 (es) *	2009-12-17	2012-06-13	Consejo Superior De Investigaciones Científicas (Csic)	Uso del raltegravir y derivados para la elaboración de medicamentos destinados al tratamiento de infecciones por herpesvirus.
ES2524380T3 (es)	2010-04-01	2014-12-05	Teva Pharmaceutical Industries Ltd.	Sales de raltegravir y formas cristalinas de las mismas
EP2552915B1 (fr) *	2010-04-01	2017-07-19	Critical Outcome Technologies Inc.	Composés pour le traitement du vih
EP2575465A4 (fr) *	2010-05-25	2013-11-20	Hetero Research Foundation	Sels de raltégravir
WO2012009446A1 (fr)	2010-07-16	2012-01-19	Concert Pharmaceuticals Inc.	Nouveaux dérivés pyrimidinecarboxamide
CN101914067B (zh) *	2010-08-26	2012-07-11	陈岱岭	N-甲基嘧啶酮的合成方法
JO3209B1 (ar) *	2010-11-05	2018-03-08	H Lundbeck As	طريقة لتصنيع نالتريكسون
WO2012103105A1 (fr)	2011-01-24	2012-08-02	Assia Chemical Industries Ltd.	Procédés de préparation du raltégravir et de ses intermédiaires dans lesdits procédés
WO2012106534A2 (fr) *	2011-02-02	2012-08-09	The Regents Of The University Of California	Inhibiteurs de l'intégrase du vih
US9163009B2 (en)	2011-04-06	2015-10-20	Lupin Limited	Salts of raltegravir
CA2833006A1 (fr) *	2011-04-22	2012-10-26	Merck Sharp & Dohme Corp.	Preparations de raltegravir de saveur masquee
US9968607B2 (en)	2011-04-25	2018-05-15	Hetero Research Foundation	Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
EP2522665A1 (fr)	2011-05-03	2012-11-14	Sandoz Ag	Sel de sodium cristallin d'un inhibiteur de l'intégrase du VIH
ES2450944T3 (es)	2011-06-01	2014-03-25	Ratiopharm Gmbh	Composición y comprimido que comprenden raltegravir
WO2013037731A1 (fr)	2011-09-16	2013-03-21	Hexal Ag	Nouvelle forme polymorphe du raltégravir potassium
CN103130788B (zh) *	2011-11-24	2015-09-02	南开大学	嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
CN103130787B (zh) *	2011-11-24	2015-06-10	南开大学	嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性
WO2013098854A2 (fr) *	2011-12-26	2013-07-04	Emcure Pharmaceuticals Limited	Synthèse de raltégravir
KR20140114406A (ko)	2012-01-25	2014-09-26	루핀 리미티드	안정한 비정질 랄테그라빌 포타슘 프리믹스 및 이의 제조 방법
WO2014064711A2 (fr) *	2012-10-22	2014-05-01	Hetero Research Foundation	Procédés d'administration de raltégravir et de compositions de raltégravir
EP2818470A1 (fr)	2013-06-27	2014-12-31	Basf Se	Co-cristeaux de raltégravir potassium
WO2015009927A1 (fr) *	2013-07-17	2015-01-22	Ratiopharm Gmbh	Sels de dolutégravir
CA2938387C (fr)	2014-02-03	2021-03-02	Mylan Laboratories Ltd	Procedes pour la preparation d'intermediaires de raltegravir
WO2015140765A1 (fr)	2014-03-21	2015-09-24	Mylan Laboratories Ltd.	Prémélange de sel de potassium de raltégravir cristallin et procédé de préparation associé
US10257840B2 (en)	2014-10-22	2019-04-09	Telefonaktiebolaget Lm Ericsson (Publ)	Operation of wireless local area network in the presence of periodic interference
US10259778B2 (en)	2014-11-10	2019-04-16	Aurobindo Pharma Ltd	Process for the preparation of raltegravir
EP3472134B1 (fr) *	2016-06-21	2021-10-20	Pharmathen S.A.	Procédé de préparation de composés utilisés comme intermédiaires pour la préparation du raltégravir
EP3512854A1 (fr)	2016-09-15	2019-07-24	Lupin Limited	Procédé de préparation de la forme 3 du potassium de raltégravir cristalline pure et stable
CN108610338A (zh) *	2016-12-12	2018-10-02	天津国际生物医药联合研究院	一种嘧啶酮酰胺类化合物的制备方法
PL3710445T3 (pl)	2017-11-14	2022-06-20	Cambrex Profarmaco Milano S.R.L.	Sposób wytwarzania raltegrawiru
WO2019236395A1 (fr) *	2018-06-06	2019-12-12	Merck Sharp & Dohme Corp.	Préparations de raltégravir
GB201907305D0 (en) *	2019-05-23	2019-07-10	Douglas Pharmaceuticals Ltd	Treatment of conditions
WO2021148992A1 (fr)	2020-01-23	2021-07-29	Lupin Limited	Compositions pharmaceutiques de raltégravir

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH624391A5 (fr) *	1976-12-14	1981-07-31	Ciba Geigy Ag
US5717097A (en)	1991-11-08	1998-02-10	Merck & Co., Inc.	HIV protease inhibitors useful for the treatment of AIDS
US5413999A (en)	1991-11-08	1995-05-09	Merck & Co., Inc.	HIV protease inhibitors useful for the treatment of AIDS
IL121789A (en) *	1996-10-03	2001-06-14	Rohm & Haas	A medicinal product for inhibiting mammalian cell tumors
TR200101886T2 (tr)	1998-12-25	2001-12-21	Shionogi & Co., Ltd.	HIV integrazını önleme aktivitesi olan aromatik heterosikl bileşimleri.
IT1318424B1 (it)	2000-03-24	2003-08-25	Unihart Corp	Composti con attivita' anti-hiv.
HUP0302367A2 (hu)	2000-10-12	2003-11-28	Merck & Co., Inc.	HIV Integráz inhibitorokként hasznos aza- és poliazanaftalenil-karboxamidok, ezeket tartalmazó gyógyszerkészítmények
GB0028483D0 (en)	2000-11-22	2001-01-10	Hoffmann La Roche	Hydroxyethylamine HIV protease inhibitors
UA77454C2 (en) *	2001-10-26	2006-12-15		N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
US7354932B2 (en)	2001-12-21	2008-04-08	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
AU2002357379A1 (en)	2001-12-21	2003-07-15	Anormed Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
DE60329318D1 (de)	2002-11-20	2009-10-29	Japan Tobacco Inc	4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
RU2329265C2 (ru)	2002-12-27	2008-07-20	Институто Ди Ричерке Ди Биолоджиа Молеколаре П.Анджелетти Спа	ТЕТРАГИДРО-4Н-ПИРИДО[1,2-а]ПИРИМИДИНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ВИЧ-ИНТЕГРАЗЫ
TW200423930A (en)	2003-02-18	2004-11-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitors
RU2382648C2 (ru) *	2004-12-03	2010-02-27	Мерк Энд Ко., Инк.	Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
JP2008521929A (ja)	2004-12-03	2008-06-26	メルクエンドカムパニーインコーポレーテッド	抗核形成剤を含有する医薬組成物
CA2588466A1 (fr)	2004-12-03	2006-06-08	Merck & Co., Inc.	Utilisation d'atazanavir afin d'ameliorer les proprietes pharmacocinetiques de medicaments metabolises par ugt1a1

2005
- 2005-02-12 UA UAA200707372A patent/UA87884C2/uk unknown
- 2005-11-24 AR ARP050104911A patent/AR052034A1/es not_active Application Discontinuation
- 2005-11-25 TW TW094141625A patent/TWI344463B/zh not_active IP Right Cessation
- 2005-11-25 MY MYPI20055516A patent/MY144320A/en unknown
- 2005-12-01 PE PE2005001398A patent/PE20061148A1/es not_active Application Discontinuation
- 2005-12-02 NZ NZ555376A patent/NZ555376A/en not_active IP Right Cessation
- 2005-12-02 US US11/293,678 patent/US7754731B2/en active Active
- 2005-12-02 KR KR1020137028450A patent/KR20130122031A/ko not_active Withdrawn
- 2005-12-02 RS RS20120021A patent/RS52197B/sr unknown
- 2005-12-02 AT AT05852866T patent/ATE518844T1/de active
- 2005-12-02 EP EP05852840A patent/EP1819700B1/fr not_active Expired - Lifetime
- 2005-12-02 AT AT05852840T patent/ATE534645T1/de active
- 2005-12-02 HR HR20120066T patent/HRP20120066T1/hr unknown
- 2005-12-02 PT PT05852840T patent/PT1819700E/pt unknown
- 2005-12-02 ME MEP-2012-21A patent/ME01985B/fr unknown
- 2005-12-02 ES ES05852866T patent/ES2370136T3/es not_active Expired - Lifetime
- 2005-12-02 GE GEAP200510157A patent/GEP20105086B/en unknown
- 2005-12-02 MX MX2007006639A patent/MX2007006639A/es active IP Right Grant
- 2005-12-02 JP JP2007544570A patent/JP4705956B2/ja not_active Expired - Lifetime
- 2005-12-02 EP EP05852866A patent/EP1819683B1/fr not_active Expired - Lifetime
- 2005-12-02 PL PL05852840T patent/PL1819700T3/pl unknown
- 2005-12-02 KR KR1020077015278A patent/KR101350420B1/ko not_active Expired - Lifetime
- 2005-12-02 DK DK05852840.7T patent/DK1819700T3/da active
- 2005-12-02 AU AU2005311671A patent/AU2005311671B8/en not_active Expired
- 2005-12-02 EA EA200701204A patent/EA012418B1/ru not_active IP Right Cessation
- 2005-12-02 WO PCT/US2005/043781 patent/WO2006060730A2/fr not_active Ceased
- 2005-12-02 WO PCT/US2005/043728 patent/WO2006060712A2/fr not_active Ceased
- 2005-12-02 SI SI200531435T patent/SI1819700T1/sl unknown
- 2005-12-02 CA CA2588398A patent/CA2588398C/fr not_active Expired - Lifetime
- 2005-12-02 BR BRPI0518760A patent/BRPI0518760A8/pt not_active Application Discontinuation
- 2005-12-02 CN CN2005800416393A patent/CN101068793B/zh not_active Expired - Lifetime
- 2005-12-02 ES ES05852840T patent/ES2375788T3/es not_active Expired - Lifetime
2007
- 2007-05-22 ZA ZA200704130A patent/ZA200704130B/xx unknown
- 2007-05-23 CR CR9146A patent/CR9146A/es not_active Application Discontinuation
- 2007-05-28 NI NI200700138A patent/NI200700138A/es unknown
- 2007-05-31 IL IL183614A patent/IL183614A/en active IP Right Grant
- 2007-06-01 TN TNP2007000215A patent/TNSN07215A1/fr unknown
- 2007-06-29 MA MA30041A patent/MA29120B1/fr unknown
- 2007-07-02 NO NO20073404A patent/NO338784B1/no unknown
2010
- 2010-06-04 US US12/793,801 patent/US8357798B2/en active Active
2012
- 2012-02-21 CY CY20121100173T patent/CY1112859T1/el unknown
2014
- 2014-04-24 AR ARP140101707A patent/AR101429A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2006060712A2 (fr)	2006-06-08
AU2005311671B8 (en)	2011-02-10
CA2588398A1 (fr)	2006-06-08
AU2005311671A1 (en)	2006-06-08
TW200631944A (en)	2006-09-16
EP1819683A2 (fr)	2007-08-22
MX2007006639A (es)	2007-06-19
CR9146A (es)	2007-10-04
TNSN07215A1 (en)	2008-11-21
BRPI0518760A8 (pt)	2017-12-12
TWI344463B (en)	2011-07-01
KR101350420B1 (ko)	2014-02-17
JP4705956B2 (ja)	2011-06-22
NO338784B1 (no)	2016-10-17
BRPI0518760A2 (pt)	2008-12-09
RS52197B (sr)	2012-10-31
DK1819700T3 (da)	2012-03-19
EA200701204A1 (ru)	2007-12-28
PE20061148A1 (es)	2006-11-09
ATE518844T1 (de)	2011-08-15
SI1819700T1 (sl)	2012-07-31
KR20070089990A (ko)	2007-09-04
WO2006060730A2 (fr)	2006-06-08
UA87884C2 (uk)	2009-08-25
AR052034A1 (es)	2007-02-28
CN101068793A (zh)	2007-11-07
PL1819700T3 (pl)	2012-04-30
EP1819700B1 (fr)	2011-11-23
AU2005311671B2 (en)	2011-01-27
NI200700138A (es)	2008-05-13
PT1819700E (pt)	2012-02-01
MY144320A (en)	2011-08-29
WO2006060712A3 (fr)	2006-09-21
CY1112859T1 (el)	2016-04-13
WO2006060730A3 (fr)	2006-08-17
EP1819700A2 (fr)	2007-08-22
US20060122205A1 (en)	2006-06-08
ME01985B (fr)	2012-10-31
JP2008521933A (ja)	2008-06-26
NZ555376A (en)	2009-11-27
WO2006060712A9 (fr)	2006-07-27
US8357798B2 (en)	2013-01-22
HK1115011A1 (en)	2008-11-14
CN101068793B (zh)	2011-05-25
ATE534645T1 (de)	2011-12-15
IL183614A (en)	2012-03-29
NO20073404L (no)	2007-07-02
ZA200704130B (en)	2008-08-27
CA2588398C (fr)	2011-07-12
IL183614A0 (en)	2007-09-20
ES2375788T3 (es)	2012-03-06
KR20130122031A (ko)	2013-11-06
US7754731B2 (en)	2010-07-13
ES2370136T3 (es)	2011-12-13
US20100249410A1 (en)	2010-09-30
AR101429A2 (es)	2016-12-21
GEP20105086B (en)	2010-10-11
EP1819683B1 (fr)	2011-08-03
HRP20120066T1 (hr)	2012-03-31
EA012418B1 (ru)	2009-10-30

Publication	Publication Date	Title
MA29120B1 (fr)	2007-12-03	Sel de potassium d'un inhibiteur de l'integrase du vih
EP1725535A4 (fr)	2009-11-25	Inhibiteurs de l'integrase du vih
EP1720856A4 (fr)	2009-11-11	Inhibiteurs de l'integrase du vih
MA28519B1 (fr)	2007-04-03	Inhibiteurs de l'integrase du vih
EP1725102A4 (fr)	2009-04-29	Inhibiteurs de l'integrase du vih
EP1881825A4 (fr)	2011-11-30	Inhibiteurs de l'intégrase du vih
EP2376080A4 (fr)	2012-07-11	Synthèse d'inhibiteurs carbamoylpyridone de l'intégrase du vih et intermédiaires
EP1713773A4 (fr)	2009-09-23	Composes de n-benzyl-3,4-dihyroxypyridine-2-carboxamide et de n-benzyl-2,3-dihydroxypyridine-4-carboxamide, utiles en tant qu'inhibiteurs de l'integrase du vih
CY2016028I2 (el)	2016-12-14	S-τριαζολυλ αλφα-μερκαπτοακετανιλιδες ως αναστολεις της αντιστροφης μεταγραφασης του ηιv
EP1931691A4 (fr)	2012-01-11	Inhibiteurs d'odcase pour le traitement du paludisme
EP1549315A4 (fr)	2007-05-23	Composes de dihydroxypyridopyrazine-1,6-diones utiles en tant qu'inhibiteurs de l'integrase du vih
EP2300433A4 (fr)	2012-03-07	Inhibiteurs de l'intégrase du vih, issus de la pyridoxine
DK1564210T3 (da)	2009-11-16	4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
EP1962708A4 (fr)	2009-12-16	Evaluation du couplage d'electrode pour ablation tissulaire
FR2871660B1 (fr)	2007-01-26	Manchette pour montre
IL179455A0 (en)	2007-05-15	Bicyclic heterocycles as hiv integrase inhibitors
EP1756114A4 (fr)	2010-05-19	Inhibiteurs de l'integrase du vih
EP1788874A4 (fr)	2010-11-24	Sels de 5-azacytidine
EP1773846A4 (fr)	2008-10-08	Inhibiteurs de la indoleamine 2,3-dioxygenase (ido)
EP1753767A4 (fr)	2010-06-30	Heterocycles bicycliques utilises comme inhibiteurs de l'integrase du hiv
EP1749008A4 (fr)	2010-07-07	Heterocycles bicycliques utilises comme inhibiteurs de l'integrase du vih
EP1701948A4 (fr)	2009-03-04	Essai d'entactogenes
EP1940406A4 (fr)	2009-11-18	Inhibiteurs du canal potassique
EP1667973A4 (fr)	2010-01-27	Inhibiteurs du canal potassique de quinoline
EP1677599A4 (fr)	2008-10-22	Composes pyridopyrrolopyrazine dione hydroxy utiles comme inhibiteurs de l'integrase du vih